Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 8/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 6/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935393 | 1.00 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL10645332 | 1.00 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL936563 | 0.86 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL30711484 | 0.86 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL5722925 | 0.86 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7346709 | 0.86 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL2108392 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL407503 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8599906 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL29445402 | 0.83 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0441116-B1 | Process and intermediates for the manufacture of optically active chroman derivatives | ASAHI DENKA KOGYO KK (JP) | 1995-04-05 | — | — | EP | claimed |
| US-5233056-A | Optically active chroman derivatives and intermediates thereof, and process for manufacturing same | ASAHI DENKA KOGYO K.K. (JP) | 1993-08-03 | — | — | US | claimed |
| EP-0441116-A2 | Process and intermediates for the manufacture of optically active chroman derivatives | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1991-08-14 | — | — | EP | claimed |
| US-8084490-B2 | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-27 | — | — | US | disclosed |
| US-5504219-A | Optically active compounds and intermediates thereof, and process for manufacturing same | ASAHI DENKA KOGYO K.K. (JP) | 1996-04-02 | — | — | US | disclosed |
| EP-0441116-B1 | Process and intermediates for the manufacture of optically active chroman derivatives | ASAHI DENKA KOGYO KK (JP) | 1995-04-05 | — | — | EP | disclosed |
| US-5352845-A | Process for manufacture of optically active saturated compounds | ASAHI DENKA KOGYO K.K. (JP) | 1994-10-04 | — | — | US | disclosed |
| US-5262552-A | Optically active compounds and intermediates thereof, and process for manufacturing same | ASAHI DENKA KOGYO K.K. (JP) | 1993-11-16 | — | — | US | disclosed |
| US-5233056-A | Optically active chroman derivatives and intermediates thereof, and process for manufacturing same | ASAHI DENKA KOGYO K.K. (JP) | 1993-08-03 | — | — | US | disclosed |
| US-5233056-A | Optically active chroman derivatives and intermediates thereof, and process for manufacturing same | ASAHI DENKA KOGYO K.K. (JP) | 1993-08-03 | — | — | US | disclosed |
| US-5112855-A | Nootropic Agents | CIBA-GEIGY CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0441116-A2 | Process and intermediates for the manufacture of optically active chroman derivatives | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1991-08-14 | — | — | EP | disclosed |
| EP-0441116-A2 | Process and intermediates for the manufacture of optically active chroman derivatives | ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1991-08-14 | — | — | EP | disclosed |
| EP-0252005-B1 | HYDROGENATED 1-BENZOOXACYCLOALKYL-PYRIDINE CARBOXYLIC-ACID COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-07-10 | — | — | EP | disclosed |
| US-4957928-A | NOOTROPIC AGENTS, COGNITION ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
| EP-0122426-B1 | OPTICALLY ACTIVE CHROMAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES | BASF Aktiengesellschaft (DE) | 1988-01-27 | — | — | EP | disclosed |
| EP-0252005-A1 | Hydrogenated 1-benzooxacycloalkyl-pyridine carboxylic-acid compounds | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
| US-4645845-A | Novel optically active chroman derivatives, their preparation and novel intermediates | BASF AKTIENGESELLSCHAFT (DE) | 1987-02-24 | — | — | US | disclosed |
| EP-0122426-A2 | Optically active chroman derivatives, process for their preparation and intermediates | BASF Aktiengesellschaft (DE) | 1984-10-24 | — | — | EP | disclosed |